Was The $47 Billion Acquisition of Genentech In 2009 A Good Deal For Roche?

By Trefis Team, Contributor Roche Holding (NASDAQ:RHHBY) acquired Genentech, a pharmaceuticals company with three blockbuster oncology drugs, in 2009 for a sum of $47 billion. Back in 2008, Genentech’s top drugs were Avastin, Rituxan, Herceptin, and Lucentis, which generated sales of over $7 billion. As of 2018, the same … …read more

Read more here::